FDA Adds Rare Vision-loss Warning To Popular GLP-1 Drugs

The FDA is adding a rare vision-loss warning to all GLP-1 drug labels, including Ozempic, Wegovy, Zepbound and Mounjaro. The warning concerns non-arteritic anterior ischemic optic neuropathy, a condition linked to reduced blood flow to the optic nerve.